NS-2359

NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,^[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.^[2] The results did not support further effort by the company.^[1] NS-2359 was also in clinical trials for the treatment of ADHD,^[3] phase II having been completed in 2007.^[4] A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.^[5]

NS-2359

Clinical data
ATC code	none
Identifiers
IUPAC name (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
PubChem CID	11408320
UNII	76H76554PA
Chemical and physical data
Formula	C15H19Cl2NO
Molar mass	300.22 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3
InChI InChI=1S/C15H19Cl2NO/c1-19-8-12-11(7-10-3-5-15(12)18-10)9-2-4-13(16)14(17)6-9/h2,4,6,10-12,15,18H,3,5,7-8H2,1H3/t10-,11+,12+,15+/m0/s1 Key:FPTPUYCHSWIWIB-FUTJPDQTSA-N
(verify)

See also

• Tesofensine